Market Currents
ArQule's (ARQL) tivantinib (ARQ 197) did not meet its primary endpoint in Phase 2 testing, says...
-
Friday, January 11, 7:37 AM ETArQule's (ARQL) tivantinib (ARQ 197) did not meet its primary endpoint in Phase 2 testing, says the company. Shares remain halted.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
